The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Professor Shares Findings from 45 Years of Lupus Research

Professor Shares Findings from 45 Years of Lupus Research

March 18, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

inflammatory cytokines like type 1 interferon, and interleukin (IL) 1 and IL-18.

You Might Also Like
  • Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
Explore This Issue
March 2018
Also By This Author
  • ACR Advocates for Affordable Drugs & Consultation Codes

Type 1 Interferons

Type 1 interferons play a role in lupus pathogenesis, because increased levels of IFN-α are found in the serum of SLE patients.2 Complexes of immunoglobulin G (IgG) and nucleic acids stimulate interferon production by plasmacytoid dendritic cells (pDCs) and B cell activation, he said. IFN-α in lupus serum promotes monocyte maturation to dendritic cells, and there is an interferon-induced gene expression signature in the peripheral blood and affected tissues in lupus patients. Patients with malignancies or viral infections who are treated with IFN-α sometimes develop lupus-like symptoms, he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a 2003 study, predisposed NZB mice were bred to lack the common receptor for type 1 interferons.3 These IFNAR-knockout NZB mice had lower mortality and profoundly reduced signs of lupus-like disease, such as anti-erythrocyte and anti-DNA autoantibodies, compared with wild-type mice, he said. In a 2012 study, NZB mice were bred to lack IFN-β to see if either it or any of the 13 IFN-α proteins mediated lupus-like disease.4 The results showed that mice with deleted IFN-β did develop disease.

“This suggests that the pathogenic effect of interferons is primarily mediated by the alpha types. Then, we set out to find if such a treatment would have any clinical relevance,” he said. In the 2012 study, researchers developed an antibody against the common receptor for type 1 interferon, called IFNAR, to treat the mice affected with lupus-like disease. The results were positive: antinuclear antibodies, anti-chromatins, kidney deposits and mononuclear cells were reduced, and the mice lived longer. “However, this treatment was initiated early in the disease process, around 12 weeks of age. If treatment was delayed to beyond 18 weeks of age, the protective effects were significantly minimized. This indicates that the role of type 1 interferons and pDCs is very likely exercised at the early stages of the disease. If we can translate these findings to the clinic, then treatment with anti-IFNAR should be complemented with additional treatments that interfere with the adaptive immune system.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Toll-Like Receptors

To understand the role of the nucleic acid-sensing, endosomal TLRs 3, 7, 8 and 9 in lupus, researchers created mice with new, mutant version of the molecule UNC93B1 called 3d.5 Normally, this molecule binds to endosomal TLRs in the endoplasmic reticulum and then transports them into the endolysosomes, said Dr. Theofilopoulos. Mice with the UNC93B1 mutation had no signaling of endosomal TLRs, and disease characteristics were profoundly reduced in the mice that carried a duplication of TLR-7, he said. Later research showed that mice with this UNC93B1 3d mutation are protected from developing lupus-like disease, and the mutation seems to broadly reduce lupus autoantibodies like anti-cardiolipin, anti-β2 glycoprotein and anti-MPO, he said.6

Pages: 1 2 3 4 5 | Single Page

Filed Under: Meeting Reports, SLE (Lupus) Tagged With: ACR/ARHP Annual Meeting, Lupus, Pathogenesis, SLEIssue: March 2018

You Might Also Like:
  • Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
  • FOCIS 2015: Research Increases Understanding of Lupus, RA
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)